By developing a risk prediction model incorporating 11 key features, we identified notable differences in the tumor immune microenvironment, IL-17 signaling pathway, and cAMP signaling pathway between high and low-risk PCa patient groups. This evidence concerns the gene IL17A and neoplasm.